The role of glutamate transport and SLC7A11 expression in tumor-associate seizures and survival in patients with malignant gliomas

Joseph R. Keen, Sharon A. Swanger, Stephen F. Traynelis, Jeffrey J. Olson

Abstract

Treatment for glioblastoma (GBM) remains largely palliative despite maximal combined approaches (surgery, radiation, and chemotherapy) with a median survival of approximately 15 months due to relentless invasion and recurrence (1).